Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ACTILYSE 2 mg is substantial. |
Clinical Added Value
| minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE. |
eNq1mF1v2jAUhu/5FVEudkcSoBTYEqqN0Q2p1Rgt2rQbZJIDmAU79Qcf+/VzCKh0ctTV4MvEyXuOfY4fv3J4s12lzhoYx5REbs0LXAdITBNM5pE7fryttt2bbiVcojU6+azlBV6t7jpxijiP3HzUmwIi3Pt5f/cZ1P/A3G7FCel0CbF48Z0UOPW+Ir64R1n+jROuKU6cFYgFTSI3k2L/1gm5YCqL7oay3zxDMYT+4c3p6HJydfo+9HOx/1CVHNgdInOtKBAjzVgyBkT0kIA5ZbuSfBtG2piPgFPJYhgisRgyusYJJNoQM5RyMAoy2yQPwNYpiDyIVtxfxituJI6WaDuCp4E+6Y9qtCe2ohpUa612vd7qBEGjWQuMQrGTpdJXQU3Cjyft6+tWp+4D8VGsunJnuGyYDykTKLVUFcx7LxvLUhwGT69WP8E8S9HOW/LMdKkQQ2oYmNr+9iaSz+CRKSClas3+0ScyTf03Zj0+4MJSxjmNelQSUUKN25HpQvQoEbAtr6gZ6MT20IsY+OVk/1Cih/xQTlMcmyJNQUcCF+PRoJxol4TBJ8RhzOzR4AcmCd3wy1PmtKqWss/2oNSKZiypTeqd9nWt2TTeRL9UC5WcMH3JaAa+4g/m52BlQGb0XKCortRLHXvyYu249zk0RimUOJ2qIVtUHx6NmbVOt7eLigGt6Jf+o2l7fJfAdg/7R600TqJjYc24awPmqhdfy7vYtVE2aQTNdqdx9Q6tsg9HBx0ZuuVC1IpZlkyPmIUQGX/v+5vNxlsgXuVIrac3Y+VHwI126peYvuLtczXt+Xkr53/hhwrWWkp9Whyibyuj6b59zSGc63oP/x/ctTaGYBLOqEWBeGsgHvQvz/Zny2st7eELxNgLs7enSGBKbNkmOdUqnnWaqLKSW6b48G02wyXXK6VtGfrF1U63Evr5tU638hd89wEv
rf7W5hSgV10SG7tV
